Wolverine for Eyes: What the Evidence Shows
What human and animal studies show about Wolverine for eyes, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- from an ingredient's studies
- Human studies
- 2
- with an outcome for eyes, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 2
- with an outcome for eyes, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 4
- with an outcome for eyes
Evidence for eyes
Each row is an outcome related to eyes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here. No study has tested Wolverine itself; rows are for each ingredient.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| TB-500: Ocular discomfort and corneal staining | At day 56, the treated group had a 35.1% greater reduction in ocular discomfort and a 59.1% greater reduction in total corneal fluorescein staining than vehicle (very small trial). | Human RCTn = 9 | Cornea 2015, PMID 25826322 |
| TB-500: Primary endpoints | Neither primary endpoint (ocular discomfort, inferior corneal staining) differed significantly between groups. | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| TB-500: Secondary endpoints | Discomfort scores in the challenge environment on day 28 were 27% lower than placebo (P=0.0244), a secondary endpoint. | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| TB-500: Corneal alkali burn | The peptide-containing hydrogel accelerated corneal epithelial regeneration and reduced inflammation in an alkali burn model; this is a formulation study. | Animal · human corneal cells in vitro plus an animal alkali burn model (species not stated in abstract) (not a human result) | ACS applied materials & interfaces 2025, PMID 41359360 |
| BPC-157: Intraocular pressure | All BPC 157 regimens (eye drops, intraperitoneal, oral) normalized intraocular pressure in this rat glaucoma model. | Animal · rat (not a human result) | Biomedicines 2021, PMID 35052769 |
Wolverine and eyes are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Eye care in plain terms
MedlinePlus frames eye care as daily habits, checkups and treatment when needed.[5]
What the blend's component peptides have been tested for in the eye
The BPC-157 component was tested in a rat glaucoma model with drops, injection or drinking water, and the authors report that intraocular pressure normalized; this is animal work on BPC-157 alone.[4]
The TB500 sequence LKKTETQ was built into a hydrogel and tested in cells and in a burn model of the cornea, with faster epithelial regrowth reported.[3]
Thymosin beta-4 eye drops (studied as RGN-259, not as TB-500) were tried in a small phase 2 trial of severe dry eye, with a larger reduction in discomfort than vehicle at the last visit.[1]
A larger phase 2 dry-eye trial of the same thymosin beta-4 drops missed both primary endpoints.[2]
For the two components of this blend, 13 PubMed records matched both sets of terms on 2 Oct 2026, and the combination file lists 1 study of the pair together (a rat Achilles tendon study), so the pair has not been tested together for eye outcomes in that list.
Calculated from search BPC-157 terms AND (TB-500 OR thymosin beta-4 terms); date 2026-10-02; count 13; studies listed for the pair 1; source our combinations data bpc-157__wolverine; page topic eye outcomes. Formula: records listed for the pair = studiesListedForThePair = 1 of count = 13
Safety reported in the eye studies
In the larger dry-eye trial no adverse events were observed among the treated subjects, but that was a thymosin beta-4 solution applied to the eye.[2]
Other peptides people research for eyes
All peptides for eyes, comparedCommon questions
Does Wolverine help with eyes?
The strongest study we summarise for eyes is human rct evidence, for an ingredient rather than the blend, across 4 studies with an outcome for eyes. A trial result is not an approval; see the legal status.
Is Wolverine approved for eyes?
No. Wolverine is not FDA approved for any use, including eyes.
What is the best peptide for eyes?
There is no single answer. Our eyes overview compares each candidate by evidence grade and legal status rather than by popularity.
Can the Wolverine stack help eyes?
The human eye data are for thymosin beta-4 drops and not for this blend, and the cited trial was small and double-masked.[1]
More on Wolverine
Sources
- 1Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 2Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.Clinical ophthalmology (Auckland, N.Z.) · 2015PMID 26056426Accessed 2 Oct 2026
- 3Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.ACS applied materials & interfaces · 2025PMID 41359360Accessed 2 Oct 2026
- 4Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.Biomedicines · 2021PMID 35052769Accessed 2 Oct 2026
- 5Official web pageOfficial web page · web page
Found an error? Report a correction.